Chronic neurological conditions (e.g., migraines and epilepsy), however, do not appear to influence GFAP levels to a degree that would be expected to confound the usefulness of GFAP as a TBI biomarker (although there are few studies relating to chronic conditions) (50). The gene discussed is GFAP; the disease is migraine disorder.